Prospects for the use of biochemical markers in placental in-growth

Abstract

Placental in-growth is a severe obstetric pathology characterized by invasive placentation and associated with a high-risk of life-threatening hemorrhage. Despite the widespread use of instrumental methods of examination, timely diagnosis of placental in-growth is a challenging issue. Here, we reviewed the existing biochemical markers used for early detection and confirmation of placental in-growth, their specificity and sensitivity, and correlation with gestational age. Significant results were found for the following substances: pregnancy-associated plasma protein A (PAPP-A) in the first trimester, alpha-fetoprotein (AFP) and human beta-chorionic gonadotropin (Beta-hCG) in the second trimester, brain natriuretic peptide, antithrombin III, plasminogen activator inhibitor type I, soluble Tie-2 receptor (endothelial cell-specific tyrosine kinase receptor), and soluble vascular endothelial growth factor receptor-2. Our findings support the use of the aforementioned biomarkers as screening method for placental in-growth in medical practice.

Keywords

placental in-growth / review / biochemical markers / pregnancy-associated plasma protein A / human beta-chorionic gonadotropin / hyperglycosylated human chorionic gonadotropin / alpha-fetoprotein

References

[1] Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta. Obstet Gynecol. 2012;120(1):207–211. doi: 10.1097/AOG.0b013e318262e340

[2] Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta // Obstet Gynecol. 2012. Vol. 120, N 1. P. 207–211. doi: 10.1097/AOG.0b013e318262e340

[3] Higgins MF, Monteith C, Foley M, O’Herlihy C. Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):54–56. doi: 10.1016/j.ejogrb.2013.08.030

[4] Higgins M.F., Monteith C., Foley M., O’Herlihy C. Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section // Eur J Obstet Gynecol Reprod Biol. 2013. Vol. 171, N 1. P. 54–56. doi: 10.1016/j.ejogrb.2013.08.030

[5] Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol. 2011;38(2):285–296. doi: 10.1016/j.clp.2011.03.010

[6] Hull A.D., Moore T.R. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management // Clin Perinatol. 2011. Vol. 38, N 2. P. 285–296. doi: 10.1016/j.clp.2011.03.010

[7] Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Main indicators of maternal and child health, the service activities of child welfare and obstetrics in the Russian Federation. Moscow; 2018. (In Russ).

[8] Поликарпов А.В., Александрова Г.А., Голубев Н.А., и др. Основные показатели здоровья матери и ребёнка, деятельность службы охраны детства и родовспоможения в Российской Федерации. Москва, 2018. 107 с.

[9] Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Main indicators of maternal and child health, the service activities of child welfare and obstetrics in the Russian Federation. Moscow; 2019. (In Russ).

[10] Поликарпов А.В., Александрова Г.А., Голубев Н.А., и др. Основные показатели здоровья матери и ребёнка, деятельность службы охраны детства и родовспоможения в Российской Федерации. Москва, 2019. 107 с.

[11] Publications Committee, Society for Maternal-Fetal Medicine; Belfort MA. Placenta accreta. Am J Obstet Gynecol. 2010;203(5):430–439. doi: 10.1016/j.ajog.2010.09.013

[12] Publications Committee, Society for Maternal-Fetal Medicine; Belfort M.A. Placenta accreta // Am J Obstet Gynecol. 2010. Vol. 203, N 5. P. 430–439. doi: 10.1016/j.ajog.2010.09.013

[13] Pan XY, Wang YP, Zheng Z, et al. A Marked Increase in Obstetric Hysterectomy for Placenta Accreta. Chin Med J. (Engl). 2015;128(16):2189–2193. doi: 10.4103/0366-6999.162508

[14] Pan X.Y., Wang Y.P., Zheng Z., et al. A Marked Increase in Obstetric Hysterectomy for Placenta Accreta // Chin Med J (Engl). 2015. Vol. 128, N 16. P. 2189–2193. doi: 10.4103/0366-6999.162508

[15] Russian Society of Obstetricians and Gynecologists, Russian Obstetrical Anesthesiologists and Intensivists Association, Federation of Anaesthesiologists and Reanimatologists. Prevention, management algorithm, anesthesia and intensive therapy for postpartum bleeding. Clinical guidelines. Moscow; 2018. (In Russ).

[16] Российское общество акушеров-гинекологов, Ассоциация акушерских анестезиологов-реаниматологов, Федерация анестезиологов и реаниматологов. Профилактика, алгоритм ведения, анестезия и интенсивная терапия при послеродовых кровотечениях. Клинические рекомендации. Москва, 2018.

[17] Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(1):27–36. doi: 10.1016/j.ajog.2017.02.050

[18] Jauniaux E., Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis // Am J Obstet Gynecol. 2017. Vol. 217, N 1. P. 27–36. doi: 10.1016/j.ajog.2017.02.050

[19] Jauniaux E, Bhide A, Kennedy A, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018;140(3):274–280. doi: 10.1002/ijgo.12408

[20] Jauniaux E., Bhide A., Kennedy A., et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening // Int J Gynaecol Obstet. 2018. Vol. 140, N 3. P. 274–280. doi: 10.1002/ijgo.12408

[21] Finberg HJ, Williams JW. Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section. J Ultrasound Med. 1992;11(7):333–343. doi: 10.7863/jum.1992.11.7.333

[22] Finberg H.J., Williams J.W. Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section // J Ultrasound Med. 1992. Vol. 11, N 7. P. 333–343. doi: 10.7863/jum.1992.11.7.333

[23] Comstock CH, Love JJ Jr, Bronsteen RA, et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy. Am J Obstet Gynecol. 2004;190(4):1135–1140. doi: 10.1016/j.ajog.2003.11.024

[24] Comstock C.H., Love J.J. Jr, Bronsteen R.A., et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy // Am J Obstet Gynecol. 2004. Vol. 190, N 4. P. 1135–1140. doi: 10.1016/j.ajog.2003.11.024

[25] Zosmer N, Jauniaux E, Bunce C, et al. Interobserver agreement on standardized ultrasound and histopathologic signs for the prenatal diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2018;140(3):326–331. doi: 10.1002/ijgo.12389

[26] Zosmer N., Jauniaux E., Bunce C., et al. Interobserver agreement on standardized ultrasound and histopathologic signs for the prenatal diagnosis of placenta accreta spectrum disorders // Int J Gynaecol Obstet. 2018. Vol. 140, N 3. P. 326–331. doi: 10.1002/ijgo.12389

[27] Jauniaux E, Alfirevic Z, Bhide AG, et al. Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. BJOG. 2019;126(1):e1–e48. doi: 10.1111/1471-0528.15306

[28] Jauniaux E., Alfirevic Z., Bhide A.G., et al. Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a // BJOG. 2019. Vol. 126, N 1. P. e1–e48. doi: 10.1111/1471-0528.15306

[29] American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018;132(6):e259–e275. doi: 10.1097/AOG.0000000000002983

[30] American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum // Obstet Gynecol. 2018. Vol. 132, N 6. P. e259–e275. doi: 10.1097/AOG.0000000000002983

[31] Bailit JL, Grobman WA, Rice MM, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125(3):683–689. doi: 10.1097/AOG.0000000000000680

[32] Bailit J.L., Grobman W.A., Rice M.M., et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly Adherent Placenta Treatments and Outcomes // Obstet Gynecol. 2015. Vol. 125, N 3. P. 683–689. doi: 10.1097/AOG.0000000000000680

[33] Fitzpatrick KE, Sellers S, Spark P, et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014;121(1):62–70; discus. 70–71. doi: 10.1111/1471-0528.12405

[34] Fitzpatrick K.E., Sellers S., Spark P., et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study // BJOG. 2014. Vol. 121, N 1. P. 62–70; discus. 70–71. doi: 10.1111/1471-0528.12405

[35] Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016;123(8):1348–1355. doi: 10.1111/1471-0528.13547

[36] Thurn L., Lindqvist P.G., Jakobsson M., et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries // BJOG. 2016. Vol. 123, N 8. P. 1348–1355. doi: 10.1111/1471-0528.13547

[37] Krantz D, Goetzl L, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452–1458. doi: 10.1016/j.ajog.2004.05.068

[38] Krantz D., Goetzl L., Simpson J.L., et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes // Am J Obstet Gynecol. 2004. Vol. 191, N 4. P. 1452–1458. doi: 10.1016/j.ajog.2004.05.068

[39] Smith GCS, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762–1767. doi: 10.1210/jcem.87.4.8430

[40] Smith G.C.S., Stenhouse E.J., Crossley J.A., et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth // J Clin Endocrinol Metab. 2002. Vol. 87, N 4. P. 1762–1767. doi: 10.1210/jcem.87.4.8430

[41] Desai N, Krantz D, Roman A, et al. Elevated first trimester PAPP-A is associated with increased risk of placenta accreta. Prenat Diagn. 2014;34(2):159–162. doi: 10.1002/pd.4277

[42] Desai N., Krantz D., Roman A., et al. Elevated first trimester PAPP-A is associated with increased risk of placenta accreta // Prenat Diagn. 2014. Vol. 34, N 2. P. 159–162. doi: 10.1002/pd.4277

[43] Thompson O, Otigbah C, Nnochiri A, Sumithran E, Spencer K. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation. BJOG. 2015;122(10):1370–1376. doi: 10.1111/1471-0528.13298

[44] Thompson O., Otigbah C., Nnochiri A., Sumithran E., Spencer K. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation // BJOG. 2015. Vol. 122, N 10. P. 1370–1376. doi: 10.1111/1471-0528.13298

[45] Büke B, Akkaya H, Demir S, et al. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. J Matern Fetal Neonatal Med. 2018;31(1):59–62. doi: 10.1080/14767058.2016.1275546

[46] Büke B., Akkaya H., Demir S., et al. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta // J Matern Fetal Neonatal Med. 2018. Vol. 31, N 1. P. 59–62. doi: 10.1080/14767058.2016.1275546

[47] Penzhoyan GA, Makukhina TB. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders. J Perinat Med. 2019;48(1):21–26. doi: 10.1515/jpm-2019-0261

[48] Penzhoyan G.A., Makukhina T.B. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders // J Perinat Med. 2019. Vol. 48, N 1. P. 21–26. doi: 10.1515/jpm-2019-0261

[49] Borovkov VA. Poetapnoe prognozirovanie vrastaniya platsenty u zhenshchin s rubtsom na matke [dissertation]. Barnaul; 2020. Avai lable from: https://www.dissercat.com/content/poetapnoe-prognozirovanie-vrastaniya-platsenty-u-zhenshchin-s-rubtsom-na-matke? (In Russ).

[50] Боровков В.А. Поэтапное прогнозирование врастания плаценты у женщин с рубцом на матке : дис. … канд. мед. наук. Барнаул, 2020. Режим доступа: https://www.dissercat.com/content/poetapnoe-prognozirovanie-vrastaniya-platsenty-u-zhenshchin-s-rubtsom-na-matke? Дата обращения: 15.06.2022.

[51] Wang F, Chen S, Wang J, et al. First trimester serum PAPP-A is associated with placenta accreta: a retrospective study. Arch Gynecol Obstet. 2021;303(3):645–652. doi: 10.1007/s00404-020-05960-1

[52] Wang F., Chen S., Wang J., et al. First trimester serum PAPP-A is associated with placenta accreta: a retrospective study // Arch Gynecol Obstet. 2021. Vol. 303, N 3. P. 645–652. doi: 10.1007/s00404-020-05960-1

[53] Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomar kers. Dis Markers. 2018;2018:1507674. doi: 10.1155/2018/1507674

[54] Bartels H.C., Postle J.D., Downey P., Brennan D.J. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers // Dis Markers. 2018. Vol. 2018. P. 1507674. doi: 10.1155/2018/1507674

[55] Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8(1):102. doi: 10.1186/1477-7827-8-102

[56] Cole L.A. Biological functions of hCG and hCG-related molecules // Reprod Biol Endocrinol. 2010. Vol. 8. P. 102. doi: 10.1186/1477-7827-8-102

[57] Berndt S, Perrier d’Hauterive S, Blacher S, et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J. 2006;20(14):2630–2632. doi: 10.1096/fj.06-5885fje

[58] Berndt S., Perrier d’Hauterive S., Blacher S., et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium // FASEB J. 2006. Vol. 20, N 14. P. 2630–2632. doi: 10.1096/fj.06-5885fje

[59] Handschuh K, Guibourdenche J, Tsatsaris V, et al. Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-gamma. Endocrinology. 2007;148(10):5011–5019. doi: 10.1210/en.2007-0286

[60] Handschuh K., Guibourdenche J., Tsatsaris V., et al. Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-gamma // Endocrinology. 2007. Vol. 148, N 10. P. 5011–5019. doi: 10.1210/en.2007-0286

[61] Hung TH, Shau WY, Hsieh CC, et al. Risk factors for placenta accreta. Obstet Gynecol. 1999;93(4):545–550. doi: 10.1016/s0029-7844(98)00460-8

[62] Hung T.H., Shau W.Y., Hsieh C.C., et al. Risk factors for placenta accreta // Obstet Gynecol. 1999. Vol. 93, N 4. P. 545–550. doi: 10.1016/s0029-7844(98)00460-8

[63] Dreux S, Salomon LJ, Muller F, Goffinet F, Oury JF; ABA Study Group, Sentilhes L. Second-trimester maternal serum markers and placenta accreta. Prenat Diagn. 2012;32(10):1010–1012. doi: 10.1002/pd.3932

[64] Dreux S., Salomon L.J., Muller F., Goffinet F., Oury J.F.; ABA Study Group, Sentilhes L. Second-trimester maternal serum markers and placenta accreta // Prenat Diagn. 2012. Vol. 32, N 10. P. 1010–1012. doi: 10.1002/pd.3932

[65] Zhou J, Li J, Yan P, et al. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Placenta. 2014;35(9):691–655. doi: 10.1016/j.placenta.2014.07.007

[66] Zhou J., Li J., Yan P., et al. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete // Placenta. 2014. Vol. 35, N 9. P. 691–695. doi: 10.1016/j.placenta.2014.07.007

[67] Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A. Se cond Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn Ther. 2019;46(3):187–192. doi: 10.1159/000492829

[68] Berezowsky A., Pardo J., Ben-Zion M., Wiznitzer A., Aviram A. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study // Fetal Diagn Ther. 2019. Vol. 46, N 3. P. 187–192. doi: 10.1159/000492829

[69] Guibourdenche J, Handschuh K, Tsatsaris V, et al. Hyperglycosylated hCG is a marker of early human trophoblast invasion. J Clin Endocrinol Metab. 2010;95(10):E240–E244. doi: 10.1210/jc.2010-0138

[70] Guibourdenche J., Handschuh K., Tsatsaris V., et al. Hyper glycosylated hCG is a marker of early human trophoblast invasion // J Clin Endocrinol Metab. 2010. Vol. 95, N 10. P. E240–E244. doi: 10.1210/jc.2010-0138

[71] Al-Khan A, Youssef YH, Feldman KM, et al. Biomarkers of abnormally invasive placenta. Placenta. 2020;91:37–42. doi: 10.1016/j.placenta.2020.01.007

[72] Al-Khan A., Youssef Y.H., Feldman K.M., et al. Biomarkers of abnormally invasive placenta // Placenta. 2020. Vol. 91. P. 37–42. doi: 10.1016/j.placenta.2020.01.007

[73] Einerson BD, Straubhar A, Soisson S, et al. Hyperglycosylated hCG and Placenta Accreta Spectrum. Am J Perinatol. 2019;36(1):22–26. doi: 10.1055/s-0038-1636501

[74] Einerson B.D., Straubhar A., Soisson S., et al. Hyperglycosylated hCG and Placenta Accreta Spectrum // Am J Perinatol. 2019. Vol. 36, N 1. P. 22–26. doi: 10.1055/s-0038-1636501

[75] Waller DK, Lustig LS, Smith AH, Hook EB. Alpha-fetoprotein: a biomarker for pregnancy outcome. Epidemiology. 1993;4(5):471–476. doi: 10.1097/00001648-199309000-00014

[76] Waller D.K., Lustig L.S., Smith A.H., Hook E.B. Alpha-fetoprotein: a biomarker for pregnancy outcome // Epidemiology. 1993. Vol. 4, N 5. P. 471–476. doi: 10.1097/00001648-199309000-00014

[77] Oztas E, Ozler S, Caglar AT, Yucel A. Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy. Kaohsiung J Med Sci. 2016;32:579–585. doi: 10.1016/j.kjms.2016.08.011

[78] Oztas E., Ozler S., Caglar A.T., Yucel A. Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy // Kaohsiung J Med Sci. 2016. Vol. 32, N 11. P. 579–585. doi: 10.1016/j.kjms.2016.08.011

[79] Ersoy AO, Oztas E, Ozler S, et al. Can venous ProBNP levels predict placenta accreta? J Matern Fetal Neonatal Med. 2016;29(24):4020–4024. doi: 10.3109/14767058.2016.1152576

[80] Ersoy A.O., Oztas E., Ozler S., et al. Can venous ProBNP levels predict placenta accreta? // J Matern Fetal Neonatal Med. 2016. Vol. 29, N 24. P. 4020–4024. doi: 10.3109/14767058.2016.1152576

[81] Shainker SA, Silver RM, Modest AM, et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol. 2020;223(3):433.e1–433.e14. doi: 10.1016/j.ajog.2020.03.019

[82] Shainker S.A., Silver R.M., Modest A.M., et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics // Am J Obstet Gynecol. 2020. Vol. 223, N 3. P. 433.e1–433.e14. doi: 10.1016/j.ajog.2020.03.019

RIGHTS & PERMISSIONS

Eco-Vector